BAX and BAK proteins are required for cyclin-dependent kinase inhibitory drugs to cause apoptosis

Autor/a

Garrofé Ochoa, Xènia

Melero Fernández de Mera, Raquel M

Fernández Gómez, Francisco J.

Ribas i Fortuny, Judit

Jordán Bueso, Joaquín

Boix Torras, Jacint

Fecha de publicación

2015-03-20T19:03:24Z

2015-03-20T19:03:24Z

2008

2015-03-20T19:03:24Z



Resumen

In previous reports we have shown in SH-SY5 cells that Olomoucine and Roscovitine, two inhibitory drugs of Cyclin Dependent Kinases, caused apoptosis independent of the extrinsic pathway. In this experimental paradigm, apoptosis was refractory to the protective effects of either Bcl-2 or Bcl-XL overexpression. We are now reporting the failure of Bcl-XL to prevent dell death was consistent with no effect on the kinetics of caspase activation and cytochrome c release. To further characterize this issue, we have discarded a direct effect of either Olomoucine or Roscovitine on mitochondrial permeability transition. Moreover, we have evidence that an intrinsic pathway took place in SH-SY5Y cells by demonstrating the mitochondrial translocation of a GFP-Bax construct upon transfection and treatment with CDK inhibitory drugs. Finally, we tested the effect of Olomoucine and Roscovitine on w.t., bax-/-, bak-/- and double bax-/-bak-/- MEFs. In w.t. MEFs, both drugs induced cell death by apoptosis in a dose-dependent manner. In bax-/-, bak-/- and, particularly, double bax-/-bak-/- MEFs, we observed the inhibition of apoptosis. In conclusion, Olomoucine and Roscovitine caused apoptosis through an intrinsic pathway with Bax and Bak proteins being involved.

Tipo de documento

Artículo
Versión aceptada

Lengua

Inglés

Materias y palabras clave

Apoptosis; Olomoucine; Bcl-2; CDK; Roscovitine; Apoptosi; Mitocondris; Apoptosis; Mitochondria

Publicado por

American Association for Cancer Research

Documentos relacionados

Versió postprint del document publicat a: https://doi.org/10.1158/1535-7163.MCT-08-0655

Molecular Cancer Therapeutics, 2008, vol. 7, num. 12, p. 3800-3806

Derechos

(c) American Association for Cancer Research, 2008

Este ítem aparece en la(s) siguiente(s) colección(ones)